Genmab — Januar 2019
-
Enablement disputes typically come into play when one party has made broad claims in a patent – for example covering a broad spectrum of antibody types against a target – but only provides detail on certain “representative” antibodies. It is used to try to claim ownership of a discovery and block other developers, but can backfire if the other party can convince a court that the patent lacks sufficient detail to be enforceable.
-
-
Tak gentogen. Her står det. Det var da de søgte patentet at de ikke gjorde de ordentligt: The claim said the German biotech mispresented to the Patent Office the reliability of the data for the anti-CD38 antibodies described in its patents in other words it obtained patents in a way that wasn’t proper.
-
-
Har kigget Jefferies seneste tal igennem som ligger til grund for deres justering af kursmål fra 1900 til 1700. hvis disse tal er et udtryk for den generelle vurdering blandt analytikerne, så kan det være at de er blevet for negative og vil blive positivt overrasket ved årsregnskabet
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind